Ryvis Pharma Private Limited, a active private limited company, was established on 26 November 2008 in New Delhi, Delhi, India. Engaging in pharmaceutical retailers & distributors within the trade sector, it holds CIN: U24232DL2008PTC185273. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹0.10 M and a paid-up capital of ₹0.10 M.
Formerly known as Vyser Pharma Private Limited. It upholds a compliant status. Its leadership includes Karuna Bhatia (Additional Director), Seema Sethi (Director), Gopal Rajan Sethi (Director). Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at 91 Springboard, B1/H3, Mohan Co-Operative, Mathura Rd, Industrial Area, Block B, New Delhi, Delhi-110044, New Delhi, Delhi, 110044.
U24232DL2008PTC185273
185273
26 November 2008
₹0.10 M
₹0.10 M
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Ryvis Pharma Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Karuna Bhatia | Additional Director | 28 Oct 2019 | Current |
| Seema Sethi | Director | 26 Nov 2008 | Current |
| Gopal Rajan Sethi | Director | 26 Nov 2008 | Current |
| Upasana Bhatia | Director | 30 Dec 2016 | Current |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Ryvis Pharma Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 9.12% decrease. The company also saw a substantial improvement in profitability, with a 42.9% increase in profit. The company's net worth observed a substantial decline by a decrease of 37.94%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Ryvis Pharma had a promoter holding of 99.98% and a public holding of 0.02%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Ryvis Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Ryvis Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ryvis Pharma's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Ryvis Pharma Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was documented.
The activity Ryvis Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi. was completed.
Karuna Bhatia was appointed as a Additional Director was appointed as a Additional Director on 28 Oct 2019 & has been associated with this company since 6 years 2 months . was recorded as a recent event.
Upasana Bhatia was appointed as a Director was appointed as a Director on 30 Dec 2016 & has been associated with this company since 9 years 19 days . was recorded as a recent event.
Progress on Seema Sethi was appointed as a Director was appointed as a Director on 26 Nov 2008 & has been associated with this company since 17 years 1 month . was documented.
Progress on Gopal Rajan Sethi was appointed as a Director was appointed as a Director on 26 Nov 2008 & has been associated with this company since 17 years 1 month . was documented.
The CIN of Ryvis Pharma Private Limited is U24232DL2008PTC185273.
Ryvis Pharma Private Limited is headquartered at 91 Springboard, B1/H3, Mohan Co-Operative, Mathura Rd, Industrial Area, Block B, New Delhi, Delhi-110044, New Delhi, Delhi, 110044.
Ryvis Pharma Private Limited was incorporated on 26 November 2008.
The current directors of Ryvis Pharma Private Limited are
The primary industry of Ryvis Pharma Private Limited is Trade.
Ryvis Pharma Private Limited is unlisted.
The authorized capital of Ryvis Pharma Private Limited is ₹0.10 M, and the paid-up capital is ₹0.10 M.
The compliance status of Ryvis Pharma Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX